Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II ...

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...

Huntsman Corporation (NYSE:HUN) will release its fourth-quarter financial results, after the closing bell, on Monday, Feb. 17, 2025. Analysts expect the Texas-based company to report a quarterly loss ...

Transactional practices have their work cut out for them in 2025 as countercyclical growth slows, Thomson Reuters' Q4 Law ...

Positive IHL-42X PK findings for the treatment of Obstructive Sleep Apnea (OSA) support future 505(b)(2) New Drug Application (NDA) submissionNew ...

Piedmont Office Realty Trust, Inc. ("Piedmont" or the "Company") (NYSE:PDM), an owner of Class A office properties located primarily in major U.S. Sunbelt markets ...

Feb. 06, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the fourth quarter and fiscal ... unreasonable effort. For example, the Company is unable ...

Revenues, Gross Margin and EPS All Surpassed Guidance Range Issued on November 7, 2024Company Q1 2025 Guidance: Revenues to Decrease 8.5% to 12.5% QoQ,Gross Margin is Expected to be Around 30.5%.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Today, the ASPCA ® (The American Society for the Prevention of Cruelty to Animals ®) released its annual report on puppy mill cruelty, which provides an analysis of U.S. Department of Agriculture ...